Prospective, randomized, open-label,clinical trial comparing the effects of febuxostat and allopurinol on blood urate levels, endothelial function and makers for obesity/oxidative stress/chronic kidney diseases

Prospective, randomized, open-label,clinical trial comparing the effects of febuxostat and allopurinol on blood urate levels, endothelial function and makers for obesity/oxidative stress/chronic kidney diseases - Prospective, randomized, open-label,clinical trial comparing the effects of febuxostat and allopurinol

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011741

Enrollment

Registered

2013-09-13

Start date

2013-09-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperuricemia

Interventions

Administration of febuxostat Administration of allopurinol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Hyperuricemic patients with 8 mg/dl or greater despite of life-style improvement for 8 weeks 2) Outpatients 3) Subjects who gave written informed consent

Exclusion criteria

Exclusion criteria: 1) Allergy against febuxostat/allopurinol 2) History of stroke, acute coronary syndrome or any cardiovascular diseases needed for inpatient-treatments within 6 months 3) Either level of aspartate aminotransaminase or alanine aminotransferase exceeds three-fold of the normal limits. 4) eGFR<30ml/min./1.73m2 5) Subjects whose doctor in charge do not agree to join the trial

Design outcomes

Primary

Measure	Time frame
Serum urate levels Flow-mediated vasodilation in forearm 12 weeks after administration	—

Secondary

Measure	Time frame
Markers indicating obesity (e.g. adiponectin), inflammation (high sensitive CRP), oxidative stress (8-OHdG/ MDA-LDL), early-staged kidney diseases (microalbuminuria) 12 weeks after administration	—

Countries

Japan

Contacts

Public ContactMakoto Ayaori

National Defense Medical College Department of Internal Medicine

ayaori@ndmc.ac.jp04-2995-1617

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026